熱門資訊> 正文
Ocular获得FDA批准进行Axxl的注册试验
2025-08-12 21:05
- Ocular Therapeutix (NASDAQ:OCUL) said it got written agreement regarding a registrational trial design from the FDA for the trial of Axpaxl in non-proliferative diabetic retinopathy treatment.
- "We look forward to providing more details about our strategy in NPDR and DME at our upcoming Investor Day on September 30th," said CEO Pravin Dugel.
- Axpaxl is being evaluated for the treatment of wet AMD, diabetic retinopathy, diabetic macular edema, and other retinal diseases.
More on Ocular Therapeutix
- Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript
- Ocular's Make-Or-Break Moment: Axpaxli Data Looms For Wet AMD Market (Upgrade)
- Ocular Therapeutix GAAP EPS of -$0.39 misses by $0.04, revenue of $13.5M beats by $0.38M
- Ocular Therapeutix Q2 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Ocular Therapeutix
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
